Vesilute Injectable
Vesilute 20 mg contains the Glu-Asp dipeptide, the smallest member of the Khavinson bioregulator family. It consists of just two amino acids—glutamic acid and aspartic acid—joined by a peptide bond. Unlike conventional receptor-binding peptides, Vesilute is proposed to act as an epigenetic regulator, penetrating cell nuclei and interacting directly with DNA to modulate gene expression in bladder and urogenital tissues.
In research contexts, Vesilute is studied for its proposed effects on bladder smooth muscle function, microcirculation in pelvic tissues, and cellular regeneration in the urinary tract. The compound was developed at the St. Petersburg Institute of Bioregulation and Gerontology and is primarily investigated in Russian-language literature. No Western regulatory agency has approved Vesilute for any human indication.
In bodybuilding and fitness contexts, Vesilute is referenced anecdotally for supporting urinary function, particularly during or after anabolic steroid cycles when prostate and bladder issues may arise. However, community usage data for Vesilute is extremely limited, and no reliable dosing protocols exist. Any such use falls outside approved indications.
Research Properties of Vesilute 20 mg
- Glu-Asp dipeptide sequence—the smallest Khavinson bioregulator
- Proposed epigenetic modulation of gene expression in bladder tissue
- Investigated for bladder smooth muscle and microcirculation support
- Lyophilized powder format for extended stability
- 20 mg per vial for research applications
Glu-Asp Dipeptide Bioregulator
Vesilute belongs to the Khavinson peptide class, a family of ultrashort peptides (2–7 amino acids) developed in Russia for proposed tissue-specific regulatory effects. The Glu-Asp sequence is specifically associated with bladder and urogenital tissue, distinguishing it from Vesugen (Lys-Glu-Asp, vascular endothelium) and other bioregulators in the same family.
The proposed mechanism involves direct interaction with DNA and histone proteins after cellular penetration. Khavinson peptides are thought to bind to specific promoter regions, relaxing chromatin structure and enabling transcription of genes associated with tissue homeostasis. This epigenetic paradigm is fundamentally different from receptor-mediated signaling used by most hormone-based compounds.
Vesilute's research profile is based primarily on Russian-language studies with limited international peer review. One observational study of 20 women with overactive bladder is described in vendor materials, reporting bladder capacity increases from 267 mL to 320 mL, but this study is not peer-reviewed or independently verifiable. No controlled clinical trials have been published.
Defining Characteristic
Epigenetic Mechanism of Action
Vesilute is proposed to act through direct DNA interaction rather than cell-surface receptor binding. This epigenetic mechanism differs fundamentally from conventional bladder medications (anticholinergics, beta-3 agonists) and from anabolic or hormonal compounds.
Vesilute 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers several Khavinson bioregulators and research peptides with different tissue targets. Vesugen is the KED tripeptide (Lys-Glu-Asp) targeting vascular endothelium, while Vesilute's Glu-Asp sequence is directed toward bladder and urogenital tissue. Testagen is the KEDG tetrapeptide investigated for endocrine regulation. Cardiogen and Bronchogen represent other organ-specific bioregulators in the same research category. These compounds share the Khavinson epigenetic paradigm but differ in their proposed tissue targets and amino acid sequences.
Typical Dosage Ranges
Common reference ranges for Vesilute are not well characterized in publicly available bodybuilding resources. Community usage data is virtually nonexistent, and the limited dose information available comes from vendor websites rather than published pharmacology. Some sources reference 10–20 mg daily for 10–20 day cycles, but these figures are not derived from controlled studies and should be treated with caution.
| Use Case |
Common Reference Range |
Frequency |
| Research (non-clinical) |
Not well characterized |
Not established |
| Vendor-suggested (unverified) |
10–20 mg |
Daily for 10–20 days |
Reconstitution & Handling
Vesilute 20 mg is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic Water is commonly referenced for reconstituting research peptides. Standard sterile technique and peptide handling practices should be observed. Reconstituted solutions are typically stored refrigerated and used within a defined timeframe.
Stacking & Research Considerations
In Khavinson bioregulator protocols, Vesilute is sometimes referenced alongside other tissue-specific peptides. Vesugen (vascular endothelium) and Prostamax (prostate) are the most commonly mentioned companions in pelvic health research contexts. However, no controlled studies have examined the safety or efficacy of these combinations.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Vesilute has not been evaluated by the FDA for safety or efficacy.
Important Safety Information
No formal safety data exists for Vesilute. The compound consists of two common amino acids, which suggests low theoretical risk, but this has not been validated by toxicology studies or controlled human trials. Pharmacokinetics (absorption, distribution, metabolism, excretion) in humans are unknown.
Important
Non-Medical Use
Non-medical use of Vesilute falls outside any approved indication. Product purity does not establish that non-medical use is safe or appropriate for an individual.
Potential Adverse Effects
Because Vesilute is proposed to interact with DNA and modulate gene expression, theoretical risks include unintended effects on cellular regulation. No systematic human safety data are available to characterize common or rare adverse effects. Reported side effects in limited sources include injection site reactions, mild fatigue, and headache, but these are not from controlled trials.
Conditions Requiring Medical Evaluation
Individuals with active urinary tract infections, autoimmune conditions, or known peptide hypersensitivity should exercise particular caution with any investigational peptide. Pregnancy and breastfeeding are contraindications due to lack of safety data. No formal contraindication list exists for Vesilute because it has not undergone Western regulatory review.
Monitoring Considerations
If Vesilute is used in any research context, monitoring of urinary function and relevant inflammatory markers may be considered, though no standardized protocol exists for this compound. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Store the lyophilized powder under recommended conditions and protect from conditions that could compromise peptide integrity. Follow standard practices for handling lyophilized peptide products and inspect the vial before reconstitution.
Keep all research peptides and injectable products out of the reach of children.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Vesilute 20 mg product, use the security code on the vial label and cross-check it on the official Dragon Pharma site. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store the lyophilized powder in a cool, dry place protected from light and moisture. The unopened vial should be kept under conditions that preserve the peptide's structural integrity until reconstitution.
Once reconstituted, Vesilute solution should be handled according to standard peptide practices. The reconstituted solution is typically less stable than the lyophilized powder.
Keep out of reach of children. Follow proper handling practices for research peptides and use appropriate sterile technique during reconstitution.
Quick Reference
Do & Don't
- Do store lyophilized powder cool and dry
- Do protect from light and moisture
- Do inspect vial before reconstitution
- Don't expose to excessive heat
- Don't freeze reconstituted solution
- Don't use if powder appears discolored
What is Vesilute 20 mg used for?
Vesilute 20 mg is a research peptide supplied as a lyophilized powder. It contains the Glu-Asp dipeptide, which is investigated for proposed epigenetic effects on bladder and urogenital tissue function. There is no FDA-approved human indication for Vesilute.
How often should Vesilute 20 mg be administered?
Common reference ranges for Vesilute administration are not well characterized in publicly available bodybuilding resources. Community usage data is virtually nonexistent, and vendor-suggested protocols (10–20 mg daily for 10–20 days) are not derived from controlled studies.
Does Vesilute 20 mg require PCT?
Vesilute is not an anabolic steroid and is not proposed to suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable to Vesilute research. Its proposed epigenetic mechanism is distinct from hormonal suppression.
What does Vesilute do?
Vesilute is proposed to penetrate cell nuclei and interact with DNA to modulate gene expression in bladder and urogenital tissues. Its research profile suggests possible effects on smooth muscle function and microcirculation, but these mechanisms remain investigational. Vesilute is not a conventional receptor-binding drug.
How long does Vesilute take to work?
No established onset timeline exists for Vesilute because it has not undergone regulatory review for any human indication. Its proposed epigenetic mechanism would theoretically involve gene expression changes that develop over days to weeks, but this is speculative.
Is Vesilute the best bioregulator peptide?
No single bioregulator peptide is universally superior. The Khavinson peptide class includes multiple compounds investigated for different tissue targets. Vesilute's research focus on bladder and urogenital tissue is distinct from other peptides in Dragon Pharma's catalog, and appropriate selection depends on the specific research context.
What is the difference between Vesilute and Vesugen?
Vesilute (Glu-Asp) and Vesugen (Lys-Glu-Asp) are both Khavinson bioregulators but have different amino acid sequences and proposed tissue targets. Vesilute is associated with bladder and urogenital tissue, while Vesugen targets vascular endothelium.
What is the difference between Vesilute and Prostamax?
Prostamax is the KEDP tetrapeptide investigated for prostate health, while Vesilute targets bladder and urogenital tissue. These compounds are sometimes referenced together in pelvic health research protocols, but their proposed targets differ.
Is 20 mg of Vesilute a lot?
20 mg is the total labeled content of the Vesilute 20 mg vial. Because no standardized human dosage exists for this research peptide, the milligram amount cannot be classified as high or low relative to established protocols. This differs from compounds with well-characterized clinical dosing.
What strength is Vesilute 20 mg?
Vesilute 20 mg by Dragon Pharma contains 20 mg of Vesilute per vial as a lyophilized powder. The vial size is 2 mL. This is a research presentation.
Can Vesilute be stacked with other peptides?
There is no established research on combining Vesilute with other peptides. In Khavinson bioregulator protocols, Vesilute is sometimes referenced alongside Vesugen or Prostamax, but these combinations are not supported by controlled studies.
No reviews found
Please log in to write Vesilute 20 mg review.
